Insiders Tell the Shockwave Story
Lithotripsy, long known for breaking up kidney stones, was adapted for other interventional applications by a team from Stanford’s Biodesign Program, leading to a big win for its founders and early investors. Now the question is, will acquirer J&J be similarly rewarded for its big bet on the novel technology? Here each of the key players tells their story.
Read Article